Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunogenicity and Safety of Fully Liquid Pentavalent Vaccine in Indian Infants
NCT01470287Phase 3Completed
- Sponsor
- Novartis
- Start
- Dec 2011
- Primary completion
- Apr 2012
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of Quinvaxem in diphtheria, Tetanus, pertussis, hepatitis B (HBV), Haemophilus influenzae type b infection (Hib), sponsored by Novartis. Started Dec 2011; status: completed.
02
Drugs
Quinvaxem
03
Conditions
diphtheriaTetanuspertussishepatitis B (HBV)Haemophilus influenzae type b infection (Hib)
Beyond the preview
Go deeper on NCT01470287.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01470287.